To appraise the clinical and cost effectiveness of isatuximab in combination with pomalidomide and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma.
 
Status In progress
Process STA 2018
ID number 1477

Provisional Schedule

Committee meeting: 2 16 July 2020
Expected publication 07 October 2020

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Sanofi (isatuximab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Forum

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Aspen (dexamethasone) (not participating)
  Celgene (pomalidomide) (not participating)
  Hameln Pharmaceuticals (dexamethasone) (not participating)
  Hospira (dexamethasone) (not participating)
  Janssen-Cilag (bortezomib)
  Novartis Pharmaceuticals (panobinostat) (not participating)
  Rosemont Pharmaceuticals (dexamethasone) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
04 June 2020 - 25 June 2020 Appraisal consultation: 1
13 May 2020 Committee meeting: 1
04 September 2019 Invitation to participate
15 February 2019 - 15 March 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
13 February 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance